Boehringer and Lilly launch type 2 diabetes drug Jardiance in US with prescription
Jardiance, a once-daily, 10mg or 25mg tablet, was approved by the US Food and Drug Administration (FDA) on 1 August 2014 as an adjunct to diet and exercise
Health innovation platform developer Aditxt and its fully owned subsidiary Ignite Proteomics have announced their plans for a business combination with a strategic partner that values the latter at an implied equity value of nearly $150m.